Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3585492rdf:typepubmed:Citationlld:pubmed
pubmed-article:3585492lifeskim:mentionsumls-concept:C0033085lld:lifeskim
pubmed-article:3585492lifeskim:mentionsumls-concept:C0003250lld:lifeskim
pubmed-article:3585492lifeskim:mentionsumls-concept:C0597879lld:lifeskim
pubmed-article:3585492lifeskim:mentionsumls-concept:C0205360lld:lifeskim
pubmed-article:3585492lifeskim:mentionsumls-concept:C1515655lld:lifeskim
pubmed-article:3585492pubmed:issue6lld:pubmed
pubmed-article:3585492pubmed:dateCreated1987-7-9lld:pubmed
pubmed-article:3585492pubmed:abstractTextRecent availability of monoclonal antibodies (MoAb) and their radiolabeling through the use of the bifunctional chelating agents (BCA) have become an alternative procedure for in vivo radioimmunodetection. Using a newly synthesized BCA, a p-carboxyethylphenylglyoxal-di(N-methylthiosemicarbazone) (CE-DTS), the coupling and technetium-99m (99mTc) labeling of monoclonal IgG against hCG were carried out. In the system presented, factors affecting stability and immunoreactivity were examined. Immunoreactivity of the original IgG (56C) was preserved by conjugating one CE-DTS molecule per molecule of IgG (56C) using the phosphorylazide method, however, 99mTc labeling pH affected the immunoreactivity and limited the 99mTc labeling reaction between pH 4.5 and 6.2. A screening of labeling conditions, such as pH, reaction time, and reducing agent system were then carried out. Technetium-99m-labeled IgG (56C), [99mTc]CE-DTS-IgG (56C), showed good stability upon incubation with mice sera and comparable mice biodistribution to that of indium-111 (111In) DTPA-IgG (56C). Thus, these results indicate the excellent potential of CE-DTS as a BCA for labeling MoAb with 99mTc.lld:pubmed
pubmed-article:3585492pubmed:languageenglld:pubmed
pubmed-article:3585492pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3585492pubmed:citationSubsetIMlld:pubmed
pubmed-article:3585492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3585492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3585492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3585492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3585492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3585492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3585492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3585492pubmed:statusMEDLINElld:pubmed
pubmed-article:3585492pubmed:monthJunlld:pubmed
pubmed-article:3585492pubmed:issn0161-5505lld:pubmed
pubmed-article:3585492pubmed:authorpubmed-author:FurukawaTTlld:pubmed
pubmed-article:3585492pubmed:authorpubmed-author:YokoyamaAAlld:pubmed
pubmed-article:3585492pubmed:authorpubmed-author:YahataTTlld:pubmed
pubmed-article:3585492pubmed:authorpubmed-author:HoriuchiKKlld:pubmed
pubmed-article:3585492pubmed:authorpubmed-author:NakashimaTTlld:pubmed
pubmed-article:3585492pubmed:authorpubmed-author:EndoKKlld:pubmed
pubmed-article:3585492pubmed:authorpubmed-author:SajiHHlld:pubmed
pubmed-article:3585492pubmed:authorpubmed-author:KoizumiMMlld:pubmed
pubmed-article:3585492pubmed:authorpubmed-author:AranoYYlld:pubmed
pubmed-article:3585492pubmed:authorpubmed-author:SakaharaHHlld:pubmed
pubmed-article:3585492pubmed:issnTypePrintlld:pubmed
pubmed-article:3585492pubmed:volume28lld:pubmed
pubmed-article:3585492pubmed:ownerNLMlld:pubmed
pubmed-article:3585492pubmed:authorsCompleteNlld:pubmed
pubmed-article:3585492pubmed:pagination1027-33lld:pubmed
pubmed-article:3585492pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:3585492pubmed:meshHeadingpubmed-meshheading:3585492-...lld:pubmed
pubmed-article:3585492pubmed:meshHeadingpubmed-meshheading:3585492-...lld:pubmed
pubmed-article:3585492pubmed:meshHeadingpubmed-meshheading:3585492-...lld:pubmed
pubmed-article:3585492pubmed:meshHeadingpubmed-meshheading:3585492-...lld:pubmed
pubmed-article:3585492pubmed:meshHeadingpubmed-meshheading:3585492-...lld:pubmed
pubmed-article:3585492pubmed:meshHeadingpubmed-meshheading:3585492-...lld:pubmed
pubmed-article:3585492pubmed:meshHeadingpubmed-meshheading:3585492-...lld:pubmed
pubmed-article:3585492pubmed:meshHeadingpubmed-meshheading:3585492-...lld:pubmed
pubmed-article:3585492pubmed:meshHeadingpubmed-meshheading:3585492-...lld:pubmed
pubmed-article:3585492pubmed:meshHeadingpubmed-meshheading:3585492-...lld:pubmed
pubmed-article:3585492pubmed:meshHeadingpubmed-meshheading:3585492-...lld:pubmed
pubmed-article:3585492pubmed:meshHeadingpubmed-meshheading:3585492-...lld:pubmed
pubmed-article:3585492pubmed:meshHeadingpubmed-meshheading:3585492-...lld:pubmed
pubmed-article:3585492pubmed:meshHeadingpubmed-meshheading:3585492-...lld:pubmed
pubmed-article:3585492pubmed:year1987lld:pubmed
pubmed-article:3585492pubmed:articleTitleTechnetium-99m-labeled monoclonal antibody with preserved immunoreactivity and high in vivo stability.lld:pubmed
pubmed-article:3585492pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3585492lld:pubmed